Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
7,245 people get DNDN articles and Market Currents by email alert.
Get email alerts on DNDN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
Business Wire (May 9, 2013)
-
-
-
-
-
Business Wire (May 6, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
Dendreon's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 1 Comment
-
Dendreon's CEO Discusses Q1 2012 Results - Earnings Call TranscriptMon, May 7, 2012 • 12 Comments
-
Dendreon's CEO Discusses Q4 2011 Results - Earnings Conference CallMon, Feb 27, 2012 • 10 Comments
-
Dendreon CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Nov 2, 2011 • 2 Comments
-
Dendreon Corporation Q2 2008 Earnings Call TranscriptWed, Sep 3, 2008
-
Dendreon Corporation Q4 2007 Earnings Call TranscriptMon, Mar 31, 2008
-
Business Wire (May 9, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Feb 25, 2013)
-
at MarketWatch.com (Jan 11, 2013)
-
at CNBC.com (Jan 11, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Dec 20, 2012)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 2, 2012)
-
at CNBC.com (Oct 29, 2012)
-
Business Wire (Oct 29, 2012)
-
Business Wire (Oct 3, 2012)
-
Business Wire (Sep 28, 2012)
DNDN vs. ETF Alternatives
Company Description
Dendreon Corporation (“Dendreon”, the “Company”, “we”, “us”, or “our”), is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 10, 8:17 AM Dendreon's (DNDN) price target is shaved to $1 by BAML's Rachael McMinn (the axe, according to Notable Calls), who says even this doesn't take into account additional potential dilution. The company's underwater $648M in convertible debt with "no clear path to profitability provides a serious challenge to keep the business in operation beyond 2014." More: Citi downgrades to Sell with $3 PT, and Blair cuts its PT to $2. Shares -4.2% to $3.86 premarket. Comment! [Healthcare, On the Move]
- Thursday, May 9, 2:37 PM Dendreon (DNDN -14.4%) retests its lows for the day as the Street begins to weigh in on its Q1 miss and dismal Provenge sales numbers. Stifel Nicolaus cuts the shares to Sell, calling Provenge "hopeless," and saying the company is likely to burn through its cash long before it ever reaches breakeven, and faces the possiblity of bankruptcy before the end of FY14. Roth Capital also downgrades the stock to Sell as well. 1 Comment [Healthcare, On the Move, Earnings]
- Thursday, May 9, 11:42 AM In its call earlier, Dendreon (DNDN -12%) CEO John Johnson attributed its big Q1 miss on Provenge sales to increased competition, with the hit coming hardest in its smaller accounts which are less experienced with injectable therapies like DNDN's. But the veracity in today's selloff may be more closely linked to DNDN's sizeable chunk of convertible notes expiring in 2014 and 2016. Without any real operating income, Seeking Alpha contributor Brian Wilson thinks shareholders are facing some massive dilution on the horizon. (Webcast). 1 Comment [Healthcare, Earnings, On the Move]
- Thursday, May 9, 10:03 AM Dendreon (DNDN -16%) plummets following its earnings miss with Provenge sales of just $67.6M vs. $82M a year ago, and against consensus of around $80M (and low-ball estimates in the low $70M area). "We are seeing an improvement in enrollments," says CEO John Johnson. "As we leverage the power of our DTC campaign, we are confident in our ability to grow Provenge year over year." The earnings call is underway. (PR) Comment! [Healthcare, On the Move, Earnings]
- Monday, February 25, 1:40 PM Dendreon (DNDN +0.5%) moves up after its Q4 easily beat estimates earlier today. Community accounts, which represent 71% of total sales, were up from 58% Y/Y, with urology +25% overall Q/Q, and oncology up 4%. Comment! [Healthcare, On the Move, Earnings]
- Thursday, February 14, 11:49 AM Dendreon (DNDN -1.6%) slips after Maxim downgraded the shares to Sell today, citing concerns over Provenge sales. The firm also lowers its price target to $4.00. 3 Comments [Healthcare, On the Move]
-
Monday, January 14, 9:09 AM
Premarket gainers: AZK +29%. CUR +14%. AVNW +13%. HWD +11%. VRNT +10%. NICE +8%. FIO +6%. FRAN +6%. DNDN +5%. ALU +6%.
Losers: NTE -11%. CRUS -6%. Comment! [On the Move] -
Friday, January 11, 12:45 PM
Midday top 10 gainers: UPIP +31%. KGJI +20%. INFY +17%. DNDN +15%. REDF +14%. FLML +14%. BBY +12%. SIFY +11%. ICAD +10%. BCRX +10%.
Midday top 10 Losers: NEWL -29%. ARQL -15%. YOD -15%. PDEX -12%. BV -11%. RGLS -10%. FARO -9%. CENX -9%. MY -9%. STXS -9%. Comment! [On the Move] - Friday, January 11, 12:36 PM Dendreon's (DNDN +15%) upside surge today may be impressive on the face of it, but it's really just a blip on the screen when you consider the stock was at $17.50 just 11 months ago. Or, for that matter, two years back when it was trading at $50. While Provenge may be the focal point of today's move, it still faces hurdles - like a $93K price tag for a round of therapy - but the real catalyst to DNDN's story may just be its takeout value. The stock has a large institutional base, with heavyweights like J.P. Morgan and Tang Capital behind it, and with its recent restructuring, the payout could be big at the stocks current price tag. Comment! [Healthcare, On the Move]
-
Friday, January 11, 9:10 AM
Premarket gainers: UPIP +30%. INFY +15%. DNDN +13%. BBY +7%.
Losers: ARQL -16%. KBR -9%. SANW -8%. OCZ -7%. JCP -6%. Comment! [On the Move] - Friday, January 11, 7:49 AM Dendreon (DNDN) +12% premarket after an upgrade to Buy with price target of $10 from Bernstein. The analysts see steady growth for the company's provenge and say the chance of takeover or mergers provide additional upside. 1 Comment [Healthcare, On the Move]
-
Wednesday, December 26, 2012, 5:57 PM
After-hours top gainers, as of 5:30 p.m.: MACK +5%. CLDX +4%. FOLD +4%. IDIX +3%. NBIX +2%.
After-hours top losers: AMBA -2%. DGAZ -2%. MRVL -2%. DNDN -2%. PRSS -1%. 1 Comment [On the Move] -
Tuesday, November 20, 2012, 5:39 PM
After-hours top gainers, as of 5:15 p.m.: MEMS +83.3%. NAVB +9.7%. VELT +6.9%. XOMA +6.3%. ANFI +6.0%.
After-hours top losers: TLYS -16.9%. ZLC -12.6%. DNDN -3.4%. MBI -2.2%. CHTR -2.1%. Comment! [On the Move] -
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] - Monday, November 5, 2012, 12:10 PM William Blair is cutting its price target to $4 from $5 on Dendreon (DNDN -5.2%) after Friday's Q3 showed Provenge sales missing expectations. The firm says sales of the drug are likely to remain challenged over the near term, and keeps an Underperform rating on the stock. CFO Doug Schiffman acknowledged in the company's earning call on Friday that the drug has faced some marketing challenges over the past quarter due in part to the departure of some key sales personnel in many of its key markets. (Transcript) 2 Comments [Healthcare, On the Move]
- Friday, November 2, 2012, 4:23 PM Shares of Dendreon (DNDN +16.1%) soared today after reporting a less-than-expected $0.33 a share net loss for the quarter. Revenues climbed 21.3% Y/Y to $78M on strength in its urology and oncology units, but the numbers still slightly missed analysts estimates by $2.7M. Comment! [Healthcare, Earnings, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Bill Maurer
Update for readers - Will have $GMCR earnings for tomorrow morning. $SODA and $DNDN articles probably coming Monday. - View all 2 replies
-
-
-
- View all 1 replies
-
joe kelly: There is nothing fun about MCP. And a pox on you for reminding me of the worst trade I ever made Mr. Maurer.
-
- View all 0 replies
-
claycombmichael
$DNDN) Looks like 4.50 was the 2013 bottom for Dendreon. Provenge!! Nothing but upside from here on out...I'm long ( DNDN ) - View all 6 replies
-
McBride: it's 4.10 right now possibly a bounce off the floor, so the resilience is still at around $3.90-$4.50 . I respect your decision to sell.
-
McBride: However you may want to follow the 3 day rule next time. Or in the case of this DNDN travesty the 3 YEAR rule. Decide then wait 3 years.
-
claycombmichael
$DNDN has hit it's 2013 Low) Nothing but upside from here on out !! That's Dendreon !! Provenge !! - View all 6 replies
-
claycombmichael: 4.o1 @this time of Day, Reminds me of Gnta) Genta,,,
-
McBride: 3.96 this morning, probably on news that Bayer's Algeta (radium-223) will be indicated in the same space as Provenge.
-
- View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
claycombmichael
$DNDN has hit it's 2013 Low) Nothing but upside from here on out !! That's Dendreon !! Provenge !! - View all 6 replies
-
claycombmichael: 4.o1 @this time of Day, Reminds me of Gnta) Genta,,,
-
McBride: 3.96 this morning, probably on news that Bayer's Algeta (radium-223) will be indicated in the same space as Provenge.
-
claycombmichael
$DNDN) Looks like 4.50 was the 2013 bottom for Dendreon. Provenge!! Nothing but upside from here on out...I'm long ( DNDN ) - View all 6 replies
-
McBride: it's 4.10 right now possibly a bounce off the floor, so the resilience is still at around $3.90-$4.50 . I respect your decision to sell.
-
McBride: However you may want to follow the 3 day rule next time. Or in the case of this DNDN travesty the 3 YEAR rule. Decide then wait 3 years.
-
Bill Maurer
Update for readers - Will have $GMCR earnings for tomorrow morning. $SODA and $DNDN articles probably coming Monday. - View all 2 replies
-
-
-
- View all 1 replies
-
joe kelly: There is nothing fun about MCP. And a pox on you for reminding me of the worst trade I ever made Mr. Maurer.
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 2 replies
-
theWinner4Us: copper prices are crashing were headed for a double dip"7/29/12 -
jimmy4winners: Looks for now a rebound the the new trillion coin will stabe the markets USG, Ford ,,both look great!!
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck!
-
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 2 replies
-
-
dave staggs: Keep in mind that this is a last resort drug. Meaning, if this doesn't work, the patient dies. Ins Co's going to get sued if deny.
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 6 replies
-
-
-
Gary Jakacky
Between AONEQ.PK and DNDN I don't know how I could have a better week! Love to see thse hyped up garbage stocks collapse! SIRI, NFLX next! :) - View all 1 replies
-
FortSumter: Really, SIRI? You could wait a long time for that one to collapse with its rabid fan base. Let us know when you go short on it.